ABT-263

ABT-263
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LKT-A0777.1 1 mg -

3 - 8 business days*

108.00€
LKT-A0777.5 5 mg -

3 - 8 business days*

277.00€
LKT-A0777.10 10 mg -

3 - 8 business days*

493.00€
 
ABT-263 is a BH3 mimetic that inhibits Bcl-2 and Bcl-xl. ABT-263's inhibition of Bcl-xl results... more
Product information "ABT-263"
ABT-263 is a BH3 mimetic that inhibits Bcl-2 and Bcl-xl. ABT-263's inhibition of Bcl-xl results in thrombocytopenia, limiting its usage. ABT-263 exhibits anticancer chemotherapeutic activity and shows some benefit in clinical trials. In chronic lymphocytic leukemia (CLL) cells, ABT-263 inhibits cell proliferation. In cellular and animal models of cancers with solid tumors, ABT-263 enhances the chemotherapeutic activity of several co-administered treatments.
Keywords: Navitoclax, A-855071
Supplier: LKT Laboratories
Supplier-Nr: A0777

Properties

Application: BH3 mimetic, Bcl-2 / Bcl-xl inhibitor
MW: 974.61 D
Purity: >98%
Format: Solid

Database Information

CAS : 923564-51-6| Matching products
KEGG ID : K02539 | Matching products

Handling & Safety

Storage: +4°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "ABT-263"
Write a review
or to review a product.
Viewed